GLYCODesign And Leo Signs Cardiovascular Collaboration

(GD) has entered into a joint venture with Ltd. (Leo) of Denmark to develop novel drug candidates for the treatment of selected cardiovascular diseases.

glycodesign inc

During the initial three-year term of the collaboration, GD and Leo will combine their respective strengths in cardiovascular research and the manufacture of drugs based on glycosylaminoglycans to accelerate the development of three cardiovascular compounds into the clinic.

Under the terms of the agreement, GD and Leo will equally share the costs of the pre-clinical and initial clinical development of compounds up to the commencement of Phase II. Leo has been granted an exclusive option to commercialize drug candidates from this collaboration in Europe and Canada.

If this option is exercised, GD will receive an undisclosed amount of milestones and royalties.

GD and Leo are actively seeking a third party pharmaceutical company to complete the later-stage development of drug candidates developed during the collaboration and to market them outside Europe and Canada.

“We are excited to be working with a prominent international pharmaceutical company such as Leo. By combining Leo’s expertise in the modification of glycosylaminoglycans and their manufacture with GD’s research and clinical leadership in thromboembolitic diseases, we will expedite the development of much needed improved cardiovascular drugs,” said Dr. Jeremy Carver, President and CEO, GLYCODesign Inc. “In addition, this collaboration will substantially increase the value of our pipeline by adding new promising cardiovascular compounds ready to enter the clinic in 2016.”

Mr. Ernst Lunding, President & CEO of Leo added, “We are very pleased to have the chance to work with GLYCODesign and their Vice President Cardiovascular Research, Dr. Jack Hirsh, a world renowned leader, researcher in thromboembolic diseases to develop new cardiovascular drugs. This collaboration will continue to build on Leo’s historic commitment to develop treatments for thromboembolic disorders, and brings us one step closer to our goal of becoming one of the world’s leading companies in the anti-thrombotic market.”

Three potential drug candidates will be developed to treat cardiovascular diseases such as the treatment and prevention of both arterial and venous thrombosis.

The goal of the collaboration is to develop drugs that are more effective and potentially safer than cardiovascular drugs currently available.

Clinical trials are planned for 2016.

Leo Pharmaceutical Products Ltd. is a wholly foundation owned company based in Denmark.

Among other things, the company engages in the development of treatments for thromoboembolic disorders, and is a major producer of heparin.

Given its commitment to the international anti- thrombotic market, Leo maintains its own integrated manufacturing from animal tissue extraction to finished product.

Through its licensing partner, DuPont Pharmaceuticals Company, Leo has recently received FDA approval for Innohep a low- molecular-weight heparin used for the treatment of deep vein thrombosis and pulmonary embolism that has been marketed by Leo in Europe over the last decade.

GLYCODesign Inc. is a privately held, Toronto-based biopharmaceutical company that discovers, develops and delivers innovative therapeutics for the treatment of cancer, cardiovascular diseases, chronic inflammation and infectious diseases.

The company is a recognized world leader in glycobiology, the scientific study of the biological role of carbohydrates in the body.

Using its expertise, GLYCODesign has assembled a rich drug pipeline with 10 programs at various stages of development.


Discount pharmacy seller of Dragon Pharma: Legit Masteron 200.

Acquire Dragon Pharma Labs of Top Quality

Propionat 100 - Bulk Price

Administration: Injection
Base Constituent: Testosterone Propionate
Produced by: Dragon Pharma
Unit: 10 x 10 mL vial (100 mg/mL)
Price: 10 x $30.00

Parabolan 100 - Bulk Price

Administration: Injection
Base Substance: Trenbolone Hexahydrobenzylcarbonate
Made by: Dragon Pharma Labs
Pack: 10 x 10 mL vial (100 mg/mL)
Price: 10 x $69.00


Synthetic Anabolic Steroidal Agent
Primary Chemical Name: Oxandrolone
Produced by: Dragon Pharma
Amount: 1 X 100 pastilles (50 mg/pill)

EQ 300 - Discount Price

Administration: Injection
Prime Ingredient: Boldenone Undecylenate
Manufacturer: Dragon Pharma LLC
Pack: 30 x 10 mL vial (300 mg/mL)
Price: 30 x $29.00

Cut Mix 150 - Discount Price

Administration: Injection
Basic Chemical Name: Testosterone Propionate, Drostanolone Propionate, Trenbolone Acetate
Made by: Dragon Pharma LLC
Pack: 30 x 10 mL vial (150 mg/mL)
Price: 30 x $36.00

NPP 150 - Discount Price

Administration: Injection
Main Component: Nandrolone Phenylpropionate
Produced by: Dragon Pharma Labs
Package: 30 x 10 mL vial (150 mg/mL)
Price: 30 x $21.00

Masteron 100 - Cheap Price

Administration: Injection
Base Ingredient: Drostanolone Di-Propionate
Manufacturer: Dragon Pharmaceuticals
Pack: 20 x 10 mL vial (100 mg/mL)
Price: 20 x $42.00

Sustanon 350 - Bulk Price

Administration: Injection
Active Ingredient: Testosterone Blend
Produced by: Dragon Pharmaceuticals
Package: 10 x 10 mL vial (350 mg/mL)
Price: 10 x $45.00

Cypionat 250

Injectable Anabolic Steroid
Primary Chemical Name: Testosterone Cypionate
Produced by: Dragon Pharma Labs
Pack: 1 X 10 ml (250 mg/ml)

Cut Long 300

Injectable Steroid for Muscle Growth
Mix of: Drostanolone Enanthate,
Testosterone Enanthate, Trenbolone Enanthate
Made by: Dragon Pharma Labs
10 mL Sterile Multi-dose Vial (300 mg/mL)

Cypionat 250 [10 Vials]

Injectable Steroid for Muscle Growth
Basic Substance: Testosterone Cypionate
Made by: Dragon Pharmaceutical
10 Vials [10 mL per Vial (250 mg/ml)]
Price: 10 x $36.00 = $360.00 in Total


Primary Component: Oxandrolone
Branded by: Dragon Pharma LLC
Amount: 100 tabs (50 mg/pastille)